Bench to Cribside: The Path for Developing a Neuroprotectant

Ramanantsoa, N, Fleiss, B, Bouslama, M, Matrot, B, Schwendimann, L, Cohen-Salmon, C, Gressens, P and Gallego, J 2013, 'Bench to Cribside: The Path for Developing a Neuroprotectant', Translational Stroke Research, vol. 4, no. 2, pp. 258-277.


Document type: Journal Article
Collection: Journal Articles

Title Bench to Cribside: The Path for Developing a Neuroprotectant
Author(s) Ramanantsoa, N
Fleiss, B
Bouslama, M
Matrot, B
Schwendimann, L
Cohen-Salmon, C
Gressens, P
Gallego, J
Year 2013
Journal name Translational Stroke Research
Volume number 4
Issue number 2
Start page 258
End page 277
Total pages 20
Publisher Springer New York LLC
Abstract The consequences of perinatal brain injury include immeasurable anguish for families and substantial ongoing costs for care and support of effected children. Factors associated with perinatal brain injury in the preterm infant include inflammation and infection, and with increasing gestational age, a higher proportion is related to hypoxic-ischemic events, such as stroke and placental abruption. Over the past decade, we have acquired new insights in the mechanisms underpinning injury and many new tools to monitor outcome in perinatal brain injury in our experimental models. By embracing these new technologies, we can expedite the screening of novel therapies. This is critical as despite enormous efforts of the research community, hypothermia is the only viable neurotherapeutic, and this procedure is limited to term birth and postcardiac arrest hypoxic-ischemic events. Importantly, experimental and preliminary data in humans also indicate a considerable therapeutic potential for melatonin against perinatal brain injury. However, even if this suggested potential is proven, the complexity of the human condition means we are likely to need additional neuroprotective and regenerative strategies. Thus, within this review, we will outline what we consider the key stages of preclinical testing and development for a neuroprotectant or regenerative neurotherapy for perinatal brain injury. We will also highlight examples of novel small animal physiological and behavioral testing that gives small animal preclinical models greater clinical relevance. We hope these new tools and an integrated bench to cribside strategic plan will facilitate the fulfillment of our overarching goal, improving the long-term brain health and quality of life for infants suffering perinatal brain injury.
Subject Neurology and Neuromuscular Diseases
Paediatrics
Keyword(s) Behavioral testing
Melatonin
Neuroprotectant
Preclinical
DOI - identifier 10.1007/s12975-012-0233-2
Copyright notice © 2012 Springer Science+Business Media New York.
ISSN 1868-4483
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Altmetric details:
Access Statistics: 4 Abstract Views  -  Detailed Statistics
Created: Thu, 31 Jan 2019, 11:26:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us